...blurb from some penny stock promoter -- likely one of Southridge's subsidiaries!...it actually caused sufficient excitement to generate a "blip" in the otherwise steady decline of CTTC's stock price.
Not even a very good blurb, actually, when you consider the references to two year old videos and news reports as well as to "possible" mention at ASCO -- of course, ignoring that CTTC has been at ASCO for 2 or 3 previous years running now and yet appears to now have had ZERO revenues the last quarter.
I say "appears," since CTTC is now over three weeks PAST the deadline of the late filing date for its 10-K and has not offered a single word of explanation.
I seriously doubt a boiler room's vacuous promotional "report" will affect CTTC's business or alter whatever "horror" is lurking on that 10-K.
Before the report, I noticed at one point the bid dropped to 22 CENTS. I suspect we'll see that again in the not too distant future.
Competitive Technologies, (OTCQB:CTTC), distributor of a non-narcotic and non-invasive medical device for the treatment of chronic pain, may be entering a "Perfect Storm" of media exposure and corporate developments in the next few weeks. The American Society of Clinical Oncology (ASCO) has an upcoming Annual meeting where promising technologies and biopharmaceutical advances are presented to the cancer medical community. These presentations can have a dramatic effect on the share prices of publicly-held companies to the degree that the SEC has asked ASCO to enforce a news embargo until May 15, when all presentations on the schedule for the ASCO meeting are posted on the ASCO website. CTTC's Calmare medical device has been in clinical studies with the Mayo Clinic, University of Wisconsin and Virginia Commonwealth University. And all three institutions are expected to release their patient data very soon. There is no guarantee that Calmare will be the subject of a presentation at the ASCO meeting, but there is speculation that at least one of the three institutions will be highlighting Calmare and its effects on chronic pain patients suffering from neuropathic pain. With only 16.4 Million shares outstanding, a recent price of $0.30 and considering the details--including TV news videos-- in the CTTC Research Report available here, CTTC is one to watch for potential gains in May.
I would add a spammer (paid by a shorter or competitor) is on a lower rung of the ladder than a promoter. Hypocrite.